Tue, Sep 16, 2014, 9:02 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • padakri padakri Dec 28, 2005 9:40 PM Flag

    CELG Upgraded to Buy with 71 - S&P

    Celgene (CELG ): Upgrades to 4 STARS (buy) from 3 STARS (hold)
    Analyst: Frank DiLorenzo, CFA
    The FDA okays Revlimid to treat patients with transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q abnormality. We expect FDA approval in multiple myeloma by mid-2006, and we project Revlimid sales of $173 million for 2006. After option expense, we still see 2006 earnings per share at 79 cents, but are raising 2007's to $1.54 from $1.14. Based on our net par value analysis, which assumes approval of Revlimid in multiple myeloma and peak U.S. Thalomid/Revlimid sales of $1.9 billion by 2012, we are raising our 12-month target price to $71 from $67.

92.57+3.11(+3.48%)Sep 16 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.